Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. short communication
  4. article
Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression
Download PDF
Download PDF
  • Short Communication
  • Open access
  • Published: 01 April 2007

Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression

  • Eun-Jung Lim1,
  • Sun-Hye Lee,
  • Jin-Gu Lee,
  • Jae-Ryong Kim,
  • Sung-Su Yun,
  • Suk-Hwan Baek &
  • …
  • ChuHee Lee 

Experimental & Molecular Medicine volume 39, pages 239–245 (2007)Cite this article

  • 2361 Accesses

  • 62 Citations

  • Metrics details

Abstract

Unmethylated CpG oligodeoxynucleotides (CpG ODNs) activate immune cells to produce immune mediators. This study demonstrates that in murine macrophage RAW 264.7 cells, CpG ODN-mediated matrix metalloproteinase-9 (MMP-9) expression is regulated at transcriptional level and requires de novo protein synthesis. Inhibition of ERK and p38 MAPK, but not JNK, results in significant decrease of CpG ODN-induced MMP-9 expression. We found that endosomal maturation inhibitors, chloroquine and bafilomycin A, block CpG ODN-induced ERK and p38 MAPK activation and the subsequent MMP-9 expression. We also observed that CpG ODN induces NF-κ B activation and NF-κ B is a downstream target of p38 MAPK. Taken together, our data demonstrate that CpG ODN triggers MMP-9 expression via TLR-9 dependent ERK and p38 MAPK activation followed by NF-κ B activation.

Similar content being viewed by others

Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity

Article 28 July 2022

TNFα induces matrix metalloproteinase-9 expression in monocytic cells through ACSL1/JNK/ERK/NF-kB signaling pathways

Article Open access 01 September 2023

Exploring molecular mechanisms of postoperative delirium through multi-omics strategies in plasma exosomes

Article Open access 27 November 2024

Article PDF

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, College of Medicine, Yeungnam University, Daegu, 705-717, Korea

    Eun-Jung Lim

Authors
  1. Eun-Jung Lim
    View author publications

    Search author on:PubMed Google Scholar

  2. Sun-Hye Lee
    View author publications

    Search author on:PubMed Google Scholar

  3. Jin-Gu Lee
    View author publications

    Search author on:PubMed Google Scholar

  4. Jae-Ryong Kim
    View author publications

    Search author on:PubMed Google Scholar

  5. Sung-Su Yun
    View author publications

    Search author on:PubMed Google Scholar

  6. Suk-Hwan Baek
    View author publications

    Search author on:PubMed Google Scholar

  7. ChuHee Lee
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Lim, EJ., Lee, SH., Lee, JG. et al. Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. Exp Mol Med 39, 239–245 (2007). https://doi.org/10.1038/emm.2007.27

Download citation

  • Published: 01 April 2007

  • Issue date: 01 April 2007

  • DOI: https://doi.org/10.1038/emm.2007.27

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • CpG-oligonucleotide
  • extracellular signal-regulated MAP kinases
  • matrix metalloproteinase 9
  • NF- κ B
  • p38 mitogen-activated protein kinases
  • Toll-like receptor 9

This article is cited by

  • Modification of the immune response by bacteriophages alters methicillin-resistant Staphylococcus aureus infection

    • Tomoya Suda
    • Tomoko Hanawa
    • Takeaki Matsuda

    Scientific Reports (2022)

  • Emerging roles of Toll-like receptor 9 in cardiometabolic disorders

    • Sachiko Nishimoto
    • Daiju Fukuda
    • Masataka Sata

    Inflammation and Regeneration (2020)

  • The role of exogenous Fibrinogen in cardiac surgery: stop bleeding or induce cardiovascular disease

    • Fatemeh Javaherforoosh Zadeh
    • Mohammadjavad Mohammadtaghizadeh
    • Hadi Rezaeeyan

    Molecular Biology Reports (2020)

  • A new hypothesis for Parkinson’s disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics

    • Julia Obergasteiger
    • Giulia Frapporti
    • Mattia Volta

    Molecular Neurodegeneration (2018)

  • Chloroquine and amodiaquine enhance AMPK phosphorylation and improve mitochondrial fragmentation in diabetic tubulopathy

    • Hye Yun Jeong
    • Jun Mo Kang
    • So-Young Lee

    Scientific Reports (2018)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited